These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 17479440

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis.
    Monami M, Marchionni N, Mannucci E.
    Diabetes Res Clin Pract; 2008 Aug; 81(2):184-9. PubMed ID: 18495286
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H, Kohlmann T, Landgraf W, Holle R, Pirk O, Scholten T.
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Insulin glargine maintains equivalent glycemic control and better lipometabolic control than NPH insulin in type 1 diabetes patients who missed a meal.
    Rosak C, Jung R, Hofmann U.
    Horm Metab Res; 2008 Aug; 40(8):544-8. PubMed ID: 18493882
    [Abstract] [Full Text] [Related]

  • 9. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products.
    Bullano MF, Al-Zakwani IS, Fisher MD, Menditto L, Willey VJ.
    Curr Med Res Opin; 2005 Feb; 21(2):291-8. PubMed ID: 15802000
    [Abstract] [Full Text] [Related]

  • 10. Dosing of insulin glargine in the treatment of type 2 diabetes.
    Barnett A.
    Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
    [Abstract] [Full Text] [Related]

  • 11. Treatment with insulin glargine does not suppress serum IGF-1.
    Slawik M, Schories M, Busse Grawitz A, Reincke M, Petersen KG.
    Diabet Med; 2006 Jul; 23(7):814-7. PubMed ID: 16842489
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study.
    De Mattia G, Laurenti O, Moretti A.
    Acta Diabetol; 2009 Mar; 46(1):67-73. PubMed ID: 19030772
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine.
    Home PD, Fritsche A, Schinzel S, Massi-Benedetti M.
    Diabetes Obes Metab; 2010 Sep; 12(9):772-9. PubMed ID: 20649629
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Incidence rates of heart failure, stroke, and acute myocardial infarction among Type 2 diabetic patients using insulin glargine and other insulin.
    Juhaeri J, Gao S, Dai WS.
    Pharmacoepidemiol Drug Saf; 2009 Jun; 18(6):497-503. PubMed ID: 19326365
    [Abstract] [Full Text] [Related]

  • 18. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.
    Hassan K, Rodriguez LM, Johnson SE, Tadlock S, Heptulla RA.
    Pediatrics; 2008 Mar; 121(3):e466-72. PubMed ID: 18299307
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.